Calyx and Invicro rebrand, usher in a new era of leadership and support to the biopharmaceutical community.
Calyx and Invicro businesses officially launched under its new corporate identity, Perceptive. The new name reflects the organization’s increased strengths and capabilities, as they consolidate their place as a global leader in the provision of discovery, imaging, and eClinical solutions and services.
Expanding on their combined 50 + -year history, Perceptive provides best-in-class specialist support to global pharmaceutical, biotech, and clinical research organizations, spanning the complete R&D lifecycle, from discovery and preclinical through clinical development to post marketing. Perceptive’s offerings include imaging biomarkers and core lab services, as well as innovative technologies in randomization and trial supply management (RTSM), analytics and software.
Perceptive’s expertise is reflected in the support of almost 12,000 clinical research trials and 800+ approvals to date, across all clinical phases and therapeutic areas, with concentrated expertise in oncology and neuroscience. Moving forward under its new name, Perceptive will continue to serve science by delivering clarity and consistency for clinical trials worldwide on delivery, speed, and results.
